<DOC>
	<DOCNO>NCT01364571</DOCNO>
	<brief_summary>This first-in-human ( Phase 1 ) Phase 2 study single vaccination one three dose level investigational vaccine Staphylococcus aureus ( SA4Ag ) . The main goal study determine safe well tolerate vaccine well describe immune response elicit vaccine healthy adult age 18 &lt; 65 year . In addition , study aim assess effect SA4Ag vaccine presence Staphylococcus aureus skin within nose , throat perineum healthy adult age 18 &lt; 65 year .</brief_summary>
	<brief_title>Evaluation Single Vaccination With One Three Ascending Dose Levels 4-Antigen Staphylococcus Aureus Vaccine ( SA4Ag ) Healthy Adults Aged 18 &lt; 65 Years</brief_title>
	<detailed_description />
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adult age 18 &lt; 65 year enrollment , determine medical history , physical examination , clinical judgment investigator eligible study . Subjects preexist chronic medical condition determine stable may include . Availability entire duration study , able comply schedule visit , treatment plan , laboratory test , study procedure include completion electronic diary ( ediary ) Day 1 Day 14 follow vaccination ( ) . Ability contact telephone study participation . All male female subject biologically capable child must agree commit use reliable method birth control duration study . Unstable chronic medical condition disease require significant change therapy hospitalization within 3 month receipt study vaccine . Serious chronic medical disorder disorder investigator 's opinion precludes subject participate study Donation blood volume 250 mL great ( exclude protocolrequired blood collection ) , donation plasma within 3 month prior enrollment . Bleeding condition associate prolonged bleeding time may contraindicate intramuscular injection blood draw include subject take anticoagulant , antiplatelet and/or antithrombotic agent except lowdose daily aspirin within 30 day enrollment 1 month postvaccination . Any contraindication vaccination vaccine component . Immunocompromised person subject currently immunosuppressive therapy history immunosuppressive therapy , include chemotherapy agent long term systemic corticosteroid . Previous administration S. aureus vaccination . Any infection proven suspect caused S. aureus within 6 month precede study vaccination . Receipt blood product immunoglobulin ( include monoclonal antibody ) within 12 month enrollment conclusion study . Participation investigational interventional study within 30 day current study begin and/or study participation . Subjects investigational site staff member subject immediate family member ( 1st degree relative ) investigational site staff member Pfizer employee directly involve conduct trial . Residence nursing home longterm care facility requirement semiskilled nursing care . For Phase 1 subject , abnormality screen hematology , coagulation and/or blood chemistry laboratory value . Women pregnant ( determined urine pregnancy test ) breastfeeding . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Staphylococcus aureus</keyword>
	<keyword>vaccine</keyword>
	<keyword>staphylococcal infection</keyword>
</DOC>